CU20200028A7 - VIRAL NUCLEOPROTEIN AND FORMULATIONS CONTAINING IT - Google Patents

VIRAL NUCLEOPROTEIN AND FORMULATIONS CONTAINING IT

Info

Publication number
CU20200028A7
CU20200028A7 CU2020000028A CU20200028A CU20200028A7 CU 20200028 A7 CU20200028 A7 CU 20200028A7 CU 2020000028 A CU2020000028 A CU 2020000028A CU 20200028 A CU20200028 A CU 20200028A CU 20200028 A7 CU20200028 A7 CU 20200028A7
Authority
CU
Cuba
Prior art keywords
nucleoprotein
rna
infectious
mass
innate immunity
Prior art date
Application number
CU2020000028A
Other languages
Spanish (es)
Inventor
Santiago Jorge Agustín Aguiar
Rubido Julio César Aguilar
Mamun Al-Mahtab
Nieto Gerardo Enrique Guillén
Martin Kächele
Mohammad Fazle Akbar Sheikh
Frank Thiele
Helal Uddin
Maarten Van-De-Klundert
Original Assignee
Ct Ingenieria Genetica Biotecnologia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Ingenieria Genetica Biotecnologia filed Critical Ct Ingenieria Genetica Biotecnologia
Priority to CU2020000028A priority Critical patent/CU20200028A7/en
Priority to CN202180043563.7A priority patent/CN115697394A/en
Priority to MX2022013148A priority patent/MX2022013148A/en
Priority to PCT/CU2021/050002 priority patent/WO2021213558A2/en
Priority to JP2022563491A priority patent/JP2023522118A/en
Publication of CU20200028A7 publication Critical patent/CU20200028A7/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24223—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

<p>Nucleoproteína que comprende ácido ribonucleico (ARN) y una proteína de origen viral donde el contenido de ARN es mayor del 20 porciento (masa:masa) y dicho ARN se encuentra protegido de la degradación dentro de una estructura semejante a virus, y donde dicha nucleoproteína activa simultáneamente los receptores de la inmunidad innata TLR3, TLR2, TLR7, TLR8 y TLR9, por lo que potencia una respuesta anti-infecciosa, anti-tumoral o anti-alérgica, o activa y entrena la inmunidad innata en la prevención o tratamiento de procesos infecciosos o alérgicos. Esta nucleoproteína se puede combinarse con otros fármacos y puede aparecer como un adyuvante o un <em>carrier</em> de antígenos vacunales,en formulaciones y en un kit para su administración mucosal.</p><p> Nucleoprotein comprising ribonucleic acid (RNA) and a protein of viral origin where the RNA content is greater than 20 percent (mass: mass) and said RNA is protected from degradation within a virus-like structure, and where said nucleoprotein simultaneously activates the innate immunity receptors TLR3, TLR2, TLR7, TLR8 and TLR9, thereby enhancing an anti-infectious, anti-tumor or anti-allergic response, or activates and trains innate immunity in the prevention or treatment of infectious or allergic processes. This nucleoprotein can be combined with other drugs and can appear as an adjuvant or a <em> carrier </em> of vaccine antigens, in formulations and in a kit for mucosal administration. </p>

CU2020000028A 2020-04-20 2020-04-20 VIRAL NUCLEOPROTEIN AND FORMULATIONS CONTAINING IT CU20200028A7 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CU2020000028A CU20200028A7 (en) 2020-04-20 2020-04-20 VIRAL NUCLEOPROTEIN AND FORMULATIONS CONTAINING IT
CN202180043563.7A CN115697394A (en) 2020-04-20 2021-04-16 Viral nucleoproteins and formulations comprising the same
MX2022013148A MX2022013148A (en) 2020-04-20 2021-04-16 Viral nucleoprotein and formulations containing same.
PCT/CU2021/050002 WO2021213558A2 (en) 2020-04-20 2021-04-16 Viral nucleoprotein and formulations containing same
JP2022563491A JP2023522118A (en) 2020-04-20 2021-04-16 Viral nucleoprotein and preparation thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU2020000028A CU20200028A7 (en) 2020-04-20 2020-04-20 VIRAL NUCLEOPROTEIN AND FORMULATIONS CONTAINING IT

Publications (1)

Publication Number Publication Date
CU20200028A7 true CU20200028A7 (en) 2021-11-04

Family

ID=77338444

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2020000028A CU20200028A7 (en) 2020-04-20 2020-04-20 VIRAL NUCLEOPROTEIN AND FORMULATIONS CONTAINING IT

Country Status (5)

Country Link
JP (1) JP2023522118A (en)
CN (1) CN115697394A (en)
CU (1) CU20200028A7 (en)
MX (1) MX2022013148A (en)
WO (1) WO2021213558A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202204803D0 (en) * 2022-04-01 2022-05-18 Univ Manchester Virus-like particles

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1450856B1 (en) * 2001-09-14 2009-11-11 Cytos Biotechnology AG Packaging of immunostimulatory cpg into virus-like particles: method of preparation and use
EP1644034B1 (en) * 2003-07-10 2011-01-12 Cytos Biotechnology AG Composition for enhancing an immune response comprising packaged virus-like particles
EP2498815A4 (en) * 2009-11-09 2014-03-19 Nat Jewish Health VACCINE COMPOSITION
EA201892212A1 (en) 2016-03-31 2019-03-29 Сентро Де Инхеньерия Хенетика И Биотекнолохия PHARMACEUTICAL COMPOSITION, WHICH INCLUDES SURFACE AND NUCLEOCAXID ANTIGENES OF THE HEPATITIS B VIRUS

Also Published As

Publication number Publication date
WO2021213558A3 (en) 2021-12-30
MX2022013148A (en) 2022-11-16
CN115697394A (en) 2023-02-03
WO2021213558A2 (en) 2021-10-28
JP2023522118A (en) 2023-05-26

Similar Documents

Publication Publication Date Title
MX2022015132A (en) Nucleic acid based combination vaccines.
ES2731899T3 (en) Composition of nasal flu vaccine
ES2293923T3 (en) INTRANASAL VACCINE AGAINST THE INFLUENZA VIRUS.
ES2562456T3 (en) Use of an adjuvant that induces a Th1 immune response to improve immune responses
CN103608036B (en) Immunological adjuvant composition comprising inulin particles
Salleh et al. Immunogenicity mechanism of mRNA vaccines and their limitations in promoting adaptive protection against SARS-CoV-2
CO2020011914A2 (en) Self-Assembling Nanostructure Vaccines
MX2024009845A (en) LIPID NANOPARTICLE VACCINES COMPRISING MESSENGER RIBONUCLEIC ACID (mRNA).
KR102141887B1 (en) Immunogenic compositions comprising silicified virus and methods of use
CO6531435A2 (en) NEW FORMULATIONS OF VACCINE THAT INCLUDES ADJUVANTS CONTAINING SAPONINA
AR109538A1 (en) VACCINE AGAINST THE SWINE FLU
ES2340163T3 (en) VIROSOMAS SIMILAR PARTICLES.
Jiang et al. Role of extracellular vesicles in influenza virus infection
BRPI0815578B8 (en) CDCA1 PEPTIDE, ITS USE AND IMMUNOGENIC COMPOSITION INCLUDING THE SAME TO INDUCE IMMUNITY, TREAT AND/OR PREVENT CANCER, AS WELL AS IN VITRO METHOD TO INDUCE AN ANTIGEN-PRESENTING CELL AND A CYTOTOXIC T-CELL (KILLER)
Chen et al. Modulatory effect of CpG oligodeoxynucleotide on a DNA vaccine against nervous necrosis virus in orange-spotted grouper (Epinephelus coioides)
WO2011005772A1 (en) Methods for preparing vesicles and formulations produced therefrom
MX2023012530A (en) COMPOSITION AND METHODS OF ADJUVATED VACCINE.
Iyer et al. Bioengineering strategies for developing vaccines against respiratory viral diseases
CL2021003211A1 (en) A modified live strain of porcine reproductive and respiratory syndrome virus (prrs), a vaccine comprising it and its use to treat prrs type ii. (divisional application no. 2123-2018)
ECSP22064620A (en) RECOMBINANT LIVE IMMUNOGENIC COMPOSITION COMPRISING THE NEWCASTLE DISEASE VIRUS (NDV) EXPRESSING THE S1 SUBUNIT AND THE RBD OF THE SARS-CoV-2 SPIKE PROTEIN
Avunje et al. Poly (I: C) and imiquimod induced immune responses and their effects on the survival of olive flounder (Paralichthys olivaceus) from viral haemorrhagic septicaemia
UY40490A (en) COMBINATION VACCINES TO PREVENT AND/OR TREAT MULTIPLE INFECTIOUS AGENTS
US7943147B2 (en) dsRNAs as influenza virus vaccine adjuvants or immuno-stimulants
MX2022013148A (en) Viral nucleoprotein and formulations containing same.
CN101300027B (en) Secretory iga and igg antibodies-inducing agent